The "gold standard" treatment for endometrial cancer is completely staged surgery, followed by radiation or chemotherapy, based on the final pathological surgical stage and requirements. In the primary treatment of endometrial cancers, hormones are rarely taken into consideration after primary surgery. Primary treatment with hormones to preserve fertility in younger women with endometrial cancer is an attractive option, and many successful cases have been reported, although the majority of them finally received definite therapy, including total hysterectomy. The role of hormone therapy is often delayed in recurrent disease; response rates to progestins and tamoxifen or aromatase inhibitors in advanced/recurrent endometrial cancers are approximately 15e20% and nearly 10%, respectively. This review is focused on updated information and recent knowledge on the use of hormones in the management of women with advanced or recurrent endometrial cancers.
Introduction
Uterine corpus cancer is the second most common cancer in the United States, 1 and its incidence has significantly increased in Taiwan in recent years. 2 Uterine corpus cancer includes endometrial cancer and uterine sarcoma, based on the distinguishing characteristics of the uterus. On the basis of biological and histopathologic variables, endometrial cancer can be further broken down into two major types, namely, Type I and Type II. Type I is strongly associated with unopposed estrogen, whereas Type II is relatively unrelated to the overproduction of estrogen. 3 In this review, we focus on the role of hormone therapy in the management of patients with advanced or recurrent endometrial cancers.
First, a brief introduction to endometrial cancer is required, for the purpose of identifying the potential population that may be benefited by hormone therapy.
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Endometrial cancer
Detailed information on endometrial cancer has been extensively reviewed in the past. 3 In brief, two types of endometrial cancer can be clearly defined, based on the distinct biological and histopathological findings (Table 1) . Type I endometrial cancer includes the following characteristics: estrogen-related tumor, favorable outcome, well-known cancer transformation, and positive immunohistochemical staining for the phosphatase and tensin homolog gene and hormone receptors. 3 By contrast, Type II endometrial cancer comprises different characteristics, including an older population, little association with estrogen, unusual histological subtypes with p53 mutations, and a strong tendency to invasion and metastasis despite minimal or no invasion within the uterine cavity, leading to advanced stage, high recurrence rates, and a poor prognosis.
Endometrial The standard surgical staging treatment for endometrial cancer includes cytology, total hysterectomy, and bilateral salpingo-oophorectomy with/without the requirement of lymph node sampling and lymph node dissection, although some modifications are made for different populations based on differences in intent and conditions, such as fertility preservation and/or very earlier stage and well-differentiated endometrioid cancer. 3 In theory, oophorectomy might be beneficial in the management of endometrial cancer, 6 because oophorectomy can remove occult ovarian metastases and decrease estrogen production. 6 In general, the majority of patients have FIGO Stage I endometrial cancer (72.6% at Taipei Veterans General Hospital) with a favorable 5-year outcome (98.7% and 90.5% for 2009 FIGO IA and IB, respectively). 4 However, the prognosis in advanced/recurrent disease is poor and presents a therapeutic challenge, even for those patients with Type I endometrial cancers. Many endometrial cancers express estrogen (ER) and/or progesterone (PR) receptors; consequently, there are numerous case reports, retrospective studies, and small Phase 2 studies that use a variety of hormonal therapies in patients with recurrent/metastatic endometrial cancers. The most commonly used agents are progestogens, tamoxifen, gonadotropin-releasing hormone agonist (GnRH agonist), and aromatase inhibitors (AIs). The following section highlights current knowledge on the use of hormonal therapy in recurrent endometrial cancer.
Diagnosis of recurrent endometrial cancer
Before addressing the topic on the use of hormones in the management of recurrent endometrial cancer, clarifying the issue of how to diagnose recurrent endometrial cancer is of paramount importance. The endometrial cancer recurrence rate ranges from 7.7% to 19%. 7 The majority of recurrences, ranging from 68% to 100%, were detected within 3 years, and the rate of symptomatic recurrence ranged from 70% to 77%. 8 Tests used routinely as part of follow-up programs are physical examination, vaginal vault cytology, chest X-ray, abdominal pelvic ultrasound, abdominal pelvic computed tomography, and CA 125. However, recurrences detected during these incidental tests ranged from 0% to 33%, suggesting that their use seems to be of low value and they should not be used without new evidence that can aid in making a decision on the most appropriate follow up for patients. 9 The diagnosis of endometrial cancer is often at an early stage, and primary treatment, often mediated through complete staging surgery, usually cures the majority of patients. In addition, postoperative adjuvant therapy, including radiation either in the form of vaginal vault brachytherapy, pelvic external beam radiation, or other modalities, may be arranged for patients at a higher risk for recurrence, such as Stage IA, Grade 3, Stage IC, or advanced stage. 7 This then raises questions, including: (1) what is an appropriate strategy for the follow up of these patients who are clinically disease-free? and (2) do differences in follow-up intervals, diagnostic interventions, clinical setting, or specialty influence patient outcomes related to local or distant recurrence, survival, or quality of life? 7 The anatomic locations of recurrences are roughly equivalent between the local pelvis and distant sites such as intra-abdominal regions and the lungs, 9 although data from one study showed two-fifths of patients with local recurrence and the three-fifths with distant metastases. 8 There is some controversy surrounding the salvage rate among recurrent patients, which ranged from 10% to 38%. 10, 11 Treatment of recurrent disease depends on the original stage, location of the recurrence, and previous treatment. 12 The majority of isolated vaginal recurrences in women with surgical Stage I endometrial cancer can be successfully salvaged with radiation therapy, with a 5-year overall survival rate of nearly 75%. 12 The prognosis of patients with distant recurrence is generally not favorable, and these patients are often treated systemically, including chemotherapy and hormone therapy. Among these treatments, hormone therapy with progestins has been a favored option because of its minimal toxicity. 12 
Progesterones/progestins
Progesterone was discovered in 1933. Its effects are mediated through interaction with the PR, a transcription factor, and member of a large family of structurally related gene products known as the nuclear receptor superfamily. 13 Two isoforms of the PR, PRA and PRB, are generated by alternative transcription and translation from the same gene, because the amino acid sequences are identical and PRB has a longer N terminus (additional 164 amino acids). Both PRA and PRB are expressed in the normal endometrium and have distinct roles.
14 For example, alternation of PR isoform expression or loss of total PR leads to hyperplasia or even tumor formation. 13 It is well known that estrogen-based hormonal therapy increases the incidence of endometrial hyperplasia and cancer, but the addition of a synthetic progestin (estrogeneprogestin therapy) prevents the development of endometrial cancer and might decrease the incidence of the risk of endometrial cancer, suggesting that progesterone is an important inducer of endometrial differentiation and an inhibitor of carcinogenesis mediated through estrogen. 15, 16 In the early 1950s, endometrial cancers were treated with progestational agents, and the objective response rate was approximately 30%. 17 The advantages of hormones are that they are less toxic, less expensive, and easier to administer than parenteral chemotherapeutic agents, although chemotherapy is the standard antineoplastic treatment option for most women with advanced or recurrent endometrial cancers, based on the results of the Gynecologic Oncology Group (GOG) clinical trial 163. 18 The GOG 163 showed 34% and 57% objective response rates for these advanced or recurrent endometrial cancers when doxorubicin plus cisplatin without or with paclitaxel was used, respectively. The Cochrane analysis of 1519 patients found that treatment consisting of more chemotherapy was associated with longer overall survival and longer progression-free survival, even though serious acute toxicities were more common in women randomized to the more intense chemotherapy regimen. 19 Frequently used regimens are medroxyprogesterone acetate (MPA; Depo-Provera), ranging from 200 to 500 mg/day, and megestrol acetate (MA; Megace), ranging from 40 to 320 mg/day. However, for those patients with recurrent endometrial cancer undergoing progestin therapy, high doses of MPA or MA seemed not to be superior to low doses of MPA or MA, because the efficacy did not increase, but the adverse effects, including edema, weight gain, and the risk of venous thromboembolism increased significantly (GOG 081). 20 In addition, the efficacy of progestin in the management of recurrent endometrial cancers was less effective (11e25%; GOG 081 and GOG 121), 21e24 compared with the original reports (30e56%). 18, 25 Furthermore, the response in cases of recurrent endometrial cancer treated with progestins is often partial and the duration is often short (a median 3.2-month progression-free survival and a median 11.1-month overall survival in GOG 081), 21 although one report showed that some patients have a progression-free survival of more than 12 months. 26 The response rate of these recurrent endometrial cancers undergoing progestin treatment can be predicted by the presence of PR in tumors, because the response rate was 37% in patients with PRpositive tumors and 8% in patients with PR-negative tumors. 21 
Some modifications of progestins
With respect to hormone receptor status in GOG 081, 21 the hypothesis 27, 28 that tamoxifen would prevent PR downregulation, and therefore improve response, especially the duration of response, thereby favorably impacting median progression-free and overall survival, was tested. An Eastern Cooperative Oncology Group Study (E4882) randomized patients to either the standard progestin therapy of MA (20% response rate: 1 complete and 3 partial among 20 patients) or the combination of MA and tamoxifen therapy (19% response rate: 1 complete and 7 partial among 42 patients) and concluded that the combination of MA and tamoxifen offers no clinical advantages over MA alone in the treatment of advanced endometrial cancer. 28 However, a Phase II study of MPA plus tamoxifen (GOG 119) showed a 33% response rate (6 complete and 13 partial among 58 patients) with a median 3-month progression-free survival and a median 13-month overall survival; therefore, the authors concluded that the combination of daily tamoxifen and intermittent weekly MPA is an active treatment for advanced or recurrent endometrial cancer. 29 Another Phase II study of an alternative course of MA and tamoxifen (GOG 153) showed a 27% response rate (12 complete and 3 partial among 56 patients), and up to 53% of the responders had a response duration of more than 20 months; therefore, the authors concluded that this regimen of alternating MA and tamoxifen is active in treating endometrial cancer and may result in a prolonged complete response in some patients. 30 Singh and colleagues further studied the relationship of ER and PR to clinical GOG 119 outcomes and concluded that ER-alpha measured in metastatic endometrial carcinoma tissue before hormonal therapy was statistically significantly related to clinical response to daily tamoxifen and intermittent MPA. 31 The aforementioned clinical trials are summarized in Table 3. 20e23,26,28e31, 38, 39 However, a recent Cochrane review questioned the value of adjuvant progestagens for endometrial cancer, because a metaanalysis of 4556 patients failed to support its use in the primary treatment of endometrial cancer. 32 This suggested that further research and development of hormonal manipulation in endometrial cancer, such as epigenetic modulation, including methylation, histone acetylation, and others, is warranted.
Other hormones
The expression of ER in endometrial cancer provides a rationale for the use of tamoxifen or other selective ER modulators (SERMs). 33 SERMs are often used in the management of breast cancer in premenopausal women and osteoporosis in postmenopausal women, with selection, activation, and suppression of ER. 16,34e37 Tamoxifen has diverse effects in the pathogenesis of endometrial cancer because of its potential therapeutic effects on an established endometrial cancer and the potential risk of inducing the formation of endometrial cancer. 35 Thigpen and colleagues used tamoxifen 20 mg two times/day in the management of advanced or recurrent endometrial cancer, with an overall response rate of 10%, a 1.9-month median progression-free survival, and an 8.8-month medial overall survival. 38 Rendina and colleagues compared the effects of tamoxifen and MPA and showed 53.4% and 56.2% response rates, respectively, for the two. 39 Rendina et al also showed promising results with combined tamoxifen and MPA therapy, with 14 (60.8%) participants in the tamoxifen group and 15 (62.5%) in the MPA group responding to the combination therapy when they suffered a relapse of endometrial cancer, experiencing a 2.7-month median progressionfree survival and 14-month overall survial. 39 Arzoxifene, a modification of raloxifene, has been studied in a small Phase II study that showed a 31% response rate in hormone-receptorpositive or well-differentiated endometrial cancer, with a median response of 13.9 months. 40 GnRH agonist has been used in the management of various kinds of benign or malignant gynecological tumors. 41e43 It is mediated either through the direct effect of the GnRHeGnRH receptor pathway or through downregulation of the GnRH receptor, producing a subsequent suppression of ovarian function and decrease of estrogen levels. Studies in the UK evaluated the efficacy of GnRH agonists in the management of recurrent endometrial cancer. 44, 45 An open Phase II observational trial showed a 35% response rate (6/17), with a median of 20 months with no adverse effects. 44 Five years later, the same group reported that the response rate was 28% in 32 patients with recurrent endometrial cancer. 45 The significantly greater response rates were in previously irradiated sites, compared with nonirradiated sites of recurrence, suggesting that GnRH agonists have a significant and durable antitumor effect in recurrent endometrial cancer. 45 A GOG trial evaluated the effect of GnRH agonist in patients with advanced and recurrent endometrial cancer, and found an 11% response rate (2 complete, 3 partial among 42 patients), with a 1.9-month median progression-free survival and 7.3-month median overall survival. 46 AIs block the aromatase enzyme, resulting in reduced estrogen levels and deprive the tumor of growth stimulation. 47 A GOG Phase II trial evaluated the effect of AIs in patients with advanced or recurrent endometrial cancer and found a 9% response rate (2 partial, 2 stable among 23 patients). 47 Although the toxicity profile was mild, anastrozole, an AI, had only minimal activity in an unselected population of patients with recurrent endometrial cancer. 47 A multicenter Phase II trial conducted by the National Cancer Institute of Canada Clinical Trials Group further showed the low response rate (9.4%, 1 complete, 2 partial among 28 patients) of letrozole (another AI) in the management of patients with advanced or recurrent endometrial cancer. 47 However, 11 patients (39%) had stable disease for a median duration of 6.7 months, suggesting that letrozole is well tolerated but has little overall activity in patients with advanced or recurrent endometrial cancer. 48 Table 4 40,44e48
shows the summary of these trials.
In conclusion, primary advanced or recurrent endometrial cancer remains an entity with a dismal outcome and with less than optimal therapeutic options. Patients with metastatic disease are not curable and should be considered for palliative chemotherapy. Some data support the use of carboplatin and paclitaxel as an acceptable alternative to cisplatin-based regimens; however, the options are limited when those patients progress after first-line treatment. 49 In these situations, hormone therapy, especially progestins with/without tamoxifen, although response rate is not satisfactory, remains a valid option for some patients with favorable histologic and molecular characteristics, because a cure is impossible and toxicity is a major concern.
With much more advanced molecular development, new avenues of treatment may enhance the effectiveness of hormone therapy for endometrial cancer.
